Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19.
METHODS: We conducted a single pretest, single posttest quasi-experiment in a multicenter health system in Michigan from 12 March to 27 March 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary composite endpoint of escalation of care from ward to intensive care unit (ICU), new requirement for mechanical ventilation, and mortality. All patients had at least 14 days of follow-up.
RESULTS: We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively. The composite endpoint occurred at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005). This treatment effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length of stay was also observed in the early corticosteroid group (5 vs 8 days, P < .001). Multivariate regression analysis demonstrated an independent reduction in the composite endpoint at 14-days controlling for other factors (adjusted odds ratio: 0.41; 95% confidence interval, .22 - .77).
CONCLUSIONS: An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation of care and improved clinical outcomes.
CLINICAL TRIALS REGISTRATION: NCT04374071.
| Errataetall: |
CommentIn: Clin Infect Dis. 2021 Apr 26;72(8):1486-1487. - PMID 32585016 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 16 vom: 19. Nov., Seite 2114-2120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fadel, Raef [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 14.12.2020 Date Revised 30.03.2024 published: Print ClinicalTrials.gov: NCT04374071 CommentIn: Clin Infect Dis. 2021 Apr 26;72(8):1486-1487. - PMID 32585016 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa601 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310097622 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310097622 | ||
| 003 | DE-627 | ||
| 005 | 20240330232510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa601 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM310097622 | ||
| 035 | |a (NLM)32427279 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fadel, Raef |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2020 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04374071 | ||
| 500 | |a CommentIn: Clin Infect Dis. 2021 Apr 26;72(8):1486-1487. - PMID 32585016 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19 | ||
| 520 | |a METHODS: We conducted a single pretest, single posttest quasi-experiment in a multicenter health system in Michigan from 12 March to 27 March 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary composite endpoint of escalation of care from ward to intensive care unit (ICU), new requirement for mechanical ventilation, and mortality. All patients had at least 14 days of follow-up | ||
| 520 | |a RESULTS: We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively. The composite endpoint occurred at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005). This treatment effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length of stay was also observed in the early corticosteroid group (5 vs 8 days, P < .001). Multivariate regression analysis demonstrated an independent reduction in the composite endpoint at 14-days controlling for other factors (adjusted odds ratio: 0.41; 95% confidence interval, .22 - .77) | ||
| 520 | |a CONCLUSIONS: An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation of care and improved clinical outcomes | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NCT04374071 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a outcomes | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 700 | 1 | |a Morrison, Austin R |e verfasserin |4 aut | |
| 700 | 1 | |a Vahia, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Zachary R |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhry, Zohra |e verfasserin |4 aut | |
| 700 | 1 | |a Bhargava, Pallavi |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Kenney, Rachel M |e verfasserin |4 aut | |
| 700 | 1 | |a Alangaden, George |e verfasserin |4 aut | |
| 700 | 1 | |a Ramesh, Mayur S |e verfasserin |4 aut | |
| 700 | 0 | |a Henry Ford COVID-19 Management Task Force |e verfasserin |4 aut | |
| 700 | 1 | |a Nauriyal, Varidhi |e investigator |4 oth | |
| 700 | 1 | |a Lakshmikanth, Jayanth |e investigator |4 oth | |
| 700 | 1 | |a Abdul Hamed, Asif |e investigator |4 oth | |
| 700 | 1 | |a Nadeem, Owais |e investigator |4 oth | |
| 700 | 1 | |a Griebe, Kristin |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Joseph M |e investigator |4 oth | |
| 700 | 1 | |a Bradley, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Uduman, Junior |e investigator |4 oth | |
| 700 | 1 | |a Hegab, Sara |e investigator |4 oth | |
| 700 | 1 | |a Swiderek, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Godfrey, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Jennings, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Gardner-Gray, Jayna |e investigator |4 oth | |
| 700 | 1 | |a Ackerman, Adam |e investigator |4 oth | |
| 700 | 1 | |a Lezotte, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Ruhala, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Samuel, Linoj |e investigator |4 oth | |
| 700 | 1 | |a Tibbetts, Robert J |e investigator |4 oth | |
| 700 | 1 | |a Brar, Indira |e investigator |4 oth | |
| 700 | 1 | |a McKinnon, John |e investigator |4 oth | |
| 700 | 1 | |a Suleyman, Geehan |e investigator |4 oth | |
| 700 | 1 | |a Yared, Nicholas |e investigator |4 oth | |
| 700 | 1 | |a Herc, Erica |e investigator |4 oth | |
| 700 | 1 | |a Williams, Jonathan |e investigator |4 oth | |
| 700 | 1 | |a Lanfranco, Odaliz Abreu |e investigator |4 oth | |
| 700 | 1 | |a Chen, Anne |e investigator |4 oth | |
| 700 | 1 | |a Zervos, Marcus |e investigator |4 oth | |
| 700 | 1 | |a Scher, Eric |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 16 vom: 19. Nov., Seite 2114-2120 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:16 |g day:19 |g month:11 |g pages:2114-2120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa601 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 16 |b 19 |c 11 |h 2114-2120 | ||